Skip to content

Dilapan-S®: A Multicenter US E-registry

Dilapan-S®: A Multicenter US E-registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04451109
Enrollment
1200
Registered
2020-06-30
Start date
2020-12-01
Completion date
2025-06-30
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Growth Retardation, Gestational Diabetes, High Blood Pressure in Pregnancy, Oligohydramnios, Post Term Pregnancy, Premature Rupture of Membrane

Keywords

induction of labour, induction of labor, labour induction, labor induction, Dilapan, dilator, cervical ripening, cervical priming, preinduction, pre-induction

Brief summary

Objective of this registry is to collect a representative set of real world data on the use of Dilapan-S® for pre-induction cervical ripening in daily clinical practice. Upon completion of the registry, relevant collected data will be analyzed and published.

Detailed description

In the US, 23% of pregnant women undergo labor induction. A recent randomized controlled trial showed that elective labor induction at term in low-risk nulliparous women is associated with a lower risk of cesarean delivery and preeclampsia, with no increase in adverse perinatal morbidities. Hence, one can assume that labor induction rates will increase. The majority of women undergoing induction have unfavorable cervixes and require cervical ripening agents. Dilapan-S®, a hygroscopic cervical dilator made from a patented hydrogel (AQUACRYL), has been used in the past for cervical ripening for early gestation uterine evacuation. Dilapan-S® was approved by the FDA for cervical ripening in the third trimester in 2015. The Dilapan-S® rods are inserted into the cervical canal, are contained within the vagina, and do not require tension. Dilapan-S® works by absorbing fluid from cervical canal cells, resulting in reversible cell membrane dehydration and softening. In addition, the increase in the rod's volume creates a mechanical stretch and leads to the release of endogenous prostaglandins, causing cervical ripening. Recently, a multicenter prospective cohort study showed that Dilapan-S® is a safe and effective method for cervical ripening in term gestations. Lastly, our group performed non-inferiority randomized clinical trial comparing Dilapan-S® to Foley balloon for cervical ripening in term pregnancies and found that Dilapan-S® is non-inferior to Foley balloon for pre-induction cervical ripening at term. The Dilapan-S® rods are inserted into the cervical canal, are contained within the vagina, and do not require tension. Dilapan-S® works by absorbing fluid from cervical canal cells, resulting in reversible cell membrane dehydration and softening. In addition, the increase in the rod's volume creates a mechanical stretch and leads to the release of endogenous prostaglandins, causing cervical ripening. Advantages of Dilapan-S® over Foley include FDA approval, safe profile, no protrusion from the introitus, no need to keep under tension and better patient satisfaction.

Interventions

DEVICEDilapan-S

Application of Dilapan-S and all other procedures regarding cervical ripening and induction of labor will be carried out as per the hospital's standard practice.

Sponsors

The University of Texas Medical Branch, Galveston
CollaboratorOTHER
Medicem Technology s.r.o.
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pregnant woman whose plan of care is induction of labor * Maternal age ≥ 18 years * Gestational age ≥ 37 +0/7 weeks * Dilapan-S® used for cervical ripening

Exclusion criteria

* Data not available for extraction

Design outcomes

Primary

MeasureTime frame
Rate of overall vaginal deliveryright after child delivery

Secondary

MeasureTime frameDescription
Rate of vaginal delivery within 36 hours36 hours
Time to reach active stage of labor defined as ≥6 cm48 hoursminutes
Change in Bishop score48 hoursscale 0-13 (positive gain in Bishop score is considered to be a positive consequence of the intervention)
Rate of vaginal delivery within 24 hours24 hours
Rate of operative vaginal deliveryright after child delivery
Rate of caesarean sectionsright after child delivery
Rate of spontaneous vaginal deliveryright after child delivery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026